Cabometyx by Exelixis for Gastric Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer.
Mon.Dec 25, 2023
130 
Effect of an Intensive Food-as-Medicine Program on Health and Health Care Use
JAMA Internal Medicine
DECEMBER 25, 2023
This randomized clinical trial examines whether an intensive food-as-medicine program can improve glycemic control and ,1rengagement with preventive health care compared with usual care among adults with diabetes and food insecurity.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Ribociclib succinate by Novartis for Oligodendroglioma: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Oligodendroglioma.
Which pharmaceutical companies have the most SPCs in Finland?
Drug Patent Watch
DECEMBER 25, 2023
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Opaganib by RedHill Biopharma for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Opaganib is under clinical development by RedHill Biopharma and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
Drug Patent Expirations for the Week of December 24, 2023
Drug Patent Watch
DECEMBER 25, 2023
COREG CR (carvedilol phosphate) Woodward Patent: 7,268,156 Expiration: Dec 27, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of December 24, 2023 appeared first on DrugPatentWatch - Make Better Decisions.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Top 3 Podcast Episodes of the Year
Pharmaceutical Commerce
DECEMBER 25, 2023
This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.
ZB-131 by ZielBio for Gallbladder Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
ZB-131 is under clinical development by ZielBio and currently in Phase II for Gallbladder Cancer.
Efineptakin alfa by NeoImmuneTech for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Solid Tumor.
Disitamab vedotin by RemeGen for Cervical Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Disitamab vedotin is under clinical development by RemeGen and currently in Phase I for Cervical Cancer.
BDTX-4933 by Black Diamond Therapeutics for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Solid Tumor.
BDTX-4933 by Black Diamond Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.
BDTX-4933 by Black Diamond Therapeutics for Thyroid Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Thyroid Cancer.
BDTX-4933 by Black Diamond Therapeutics for Central Nervous System (CNS) Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Central Nervous System (CNS) Tumor.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BDTX-4933 by Black Diamond Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Metastatic Colorectal Cancer.
Y-101D by Wuhan YZY Biopharma for Gastric Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Gastric Cancer.
Y-101D by Wuhan YZY Biopharma for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).
Y-101D by Wuhan YZY Biopharma for Metastatic Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Colorectal Cancer.
PRGN-3007 by Precigen for Hematological Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Hematological Tumor.
Dupilumab by Regeneron Pharmaceuticals for Atopic Keratoconjunctivitis: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Atopic Keratoconjunctivitis.
Capivasertib by AstraZeneca for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Capivasertib is under clinical development by AstraZeneca and currently in Phase I for Solid Tumor.
Capivasertib by AstraZeneca for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Triple-Negative Breast Cancer (TNBC).
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Taladegib by Endeavor BioMedicines for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Taladegib is under clinical development by Endeavor BioMedicines and currently in Phase II for Idiopathic Pulmonary Fibrosis.
Opaganib by RedHill Biopharma for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Opaganib is under clinical development by RedHill Biopharma and currently in Phase I for Solid Tumor.
Ribociclib succinate by Novartis for Prostate Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Prostate Cancer.
Ribociclib succinate by Novartis for Mantle Cell Lymphoma: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Mantle Cell Lymphoma.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Ribociclib succinate by Novartis for Anaplastic Astrocytoma: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase I for Anaplastic Astrocytoma.
Ribociclib succinate by Novartis for Medulloblastoma: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Medulloblastoma.
Nivolumab by Bristol-Myers Squibb for Myelodysplastic Syndrome: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Myelodysplastic Syndrome.
Dabrafenib mesylate by Novartis for Gastrointestinal Stromal Tumor (GIST): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Dabrafenib mesylate is under clinical development by Novartis and currently in Phase II for Gastrointestinal Stromal Tumor (GIST).
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content